Evidence map›Paper›PMID 36522339›Full record

ArticleCell death & disease2022

Inhibition of p21 activates Akt kinase to trigger ROS-induced autophagy and impacts on tumor growth rate.

Mayank Maheshwari, Nisha Yadav, Mohammad Hasanain, Praveen Pandey, Rohit Sahai, Kuldeep Choyal, Akhilesh Singh, Mushtaq A Nengroo, Krishan K Saini, Deepak Kumar and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. LncRNA TMEM99 Complexes with IGF2BP2 to Inhibit Autophagy in Lung Adenocarcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. The Emerging Role of p21 in Diabetes and Related Metabolic Disorders.International journal of molecular sciences · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Mayank Maheshwari *Cancer Biology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Nisha Yadav *Cancer Biology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Mohammad HasanainCancer Biology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Praveen PandeyCancer Biology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Rohit SahaiElectron Microscopy Unit, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Kuldeep ChoyalCancer Biology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Akhilesh SinghCancer Biology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Mushtaq A NengrooCancer Biology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Krishan K SainiCancer Biology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Deepak KumarCancer Biology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Kalyan MitraAcademy of Scientific and Innovative Research, Ghaziabad, Uttar Pradesh, 201002, India.
Dipak DattaCancer Biology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.ORCID 0000-0001-7540-8543
Jayanta SarkarCancer Biology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India. j_sarkar@cdri.res.in.ORCID 0000-0002-9905-7722
Central Drug Research Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Owing to its ability to induce cellular senescence, inhibit PCNA, and arrest cell division cycle by negatively regulating CDKs as well as being a primary target of p53, p21 is traditionally considered a tumor suppressor. Nonetheless, several reports in recent years demonstrated its pro-oncogenic activities such as apoptosis inhibition by cytosolic p21, stimulation of cell motility, and promoting assembly of cyclin D-CDK4/6 complex. These opposing effects of p21 on cell proliferation, supported by the observations of its inconsistent expression in human cancers, led to the emergence of the concept of "antagonistic duality" of p21 in cancer progression. Here we demonstrate that p21 negatively regulates basal autophagy at physiological concentration. Akt activation, upon p21 attenuation, driven ROS accumulation appears to be the major underlying mechanism in p21-mediated modulation of autophagy. We also find p21, as a physiological inhibitor of autophagy, to have oncogenic activity during early events of tumor development while its inhibition favors survival and growth of cancer cells in the established tumor. Our data, thereby, reveal the potential role of autophagy in antagonistic functional duality of p21 in cancer.

Indexed as

Proto-Oncogene Proteins c-aktTumor Suppressor Protein p53AutophagyCyclin-Dependent Kinase Inhibitor p21HumansReactive Oxygen SpeciesCyclin-Dependent Kinase Inhibitor p21Proto-Oncogene Proteins c-aktReactive Oxygen SpeciesTumor Suppressor Protein p53

Identifiers

PMID36522339
PMCPMC9755229
OpenAlexW4311763529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.